Documents

in page functions

01 December 2010

GAVI Alliance monitoring and evaluation framework and strategy 2011-2015

The Monitoring and Evaluation Framework and Strategy is designed to contribute to meeting the GAVI Alliance’s diverse information needs, including those related to internal business processes, support to countries and overall effectiveness, efficiency and impact.

01 December 2010

GAVI Alliance Strategy and Business Plan 2011-2015

This GAVI Alliance Business Plan 2011-2015 describes the actions to be undertaken to achieve the 2011-2015 Strategy, while also laying out the context and challenges for the coming years.

29 October 2010

Baseline Study for pneumococcal vaccine AMC

The goal of the AMC baseline study was to establish the environment prior to the AMC with baseline estimates for a selection of indicators related to the objectives of the AMC and to model counterfactual scenarios to ascertain the potential impact of the AMC vis-a-vis traditional financial and procurement strategies.

29 October 2010

AMC Baseline Study

The AMC Baseline Study presents an innovative new approach to public health funding as a way of stimulating and accelerating the development and manufacture of vaccines for developing countries.

01 October 2010

Evaluation Advisory Committee report to the Board on the Second GAVI Evaluation

The Committee's overall assessment is that this is a credible and useful evaluation. The evaluation has yielded a number of important insights that will prove useful to the Board and Alliance as it prepares for and then implements its new strategy for the 2011-15 period.

13 September 2010

Supporting Paper 5: Progress against recommendations made by the Phase I Evaluation

Table presenting the key recommendations made by the Phase 1 evaluation and the GAVI Secretariat response. In addition, CEPA has interviewed Secretariat colleagues to understand progress made to date against these recommendations, which is noted in the final column labelled ‘implementation progress’.

13 September 2010

Supporting Paper 4.1: Bangladesh country study report

The report provides contextual information on Bangladesh’s health and immunisation sector, and assesses the results and value add of GAVI programs in the country from the country stakeholders’ perspective.

13 September 2010

Supporting Paper 10.3: SG4 report annexes

Supporting paper 10.3 of the second GAVI evaluation.

13 September 2010

Supporting Paper 1: Bibliography

Bibliography to the second GAVI evaluation.

13 September 2010

Second GAVI evaluation: Strategic Goal 4 report

This report provides the detailed analysis and evaluation material for Strategic Goal (SG) 4 in GAVI Phase II (2006-2010). GAVI's SG4 is: "to increase and assess the added value of GAVI as a public private global health partnership through improved efficiency, increased advocacy and continued innovation."

13 September 2010

Supporting Paper 10.2: SG3 report annexes

Supporting paper 10.2 of the second GAVI evaluation.

13 September 2010

Second GAVI evaluation: List of support papers

List of supporting papers for the second GAVI evaluation.

13 September 2010

13 September 2010

Supporting Paper 4.5: Uzbekistan country study report

The report provides contextual information on Uzbekistan, in terms of its health and immunisation sector and assesses the results and value add of GAVI programs in the country.

13 September 2010

Supporting Paper 4.4: Bolivia country study report

The report provides contextual information on Bolivia’s health and immunisation sector, and assesses the results and value add of GAVI programs from country stakeholders’ perspectives.

13 September 2010

13 September 2010

Supporting Paper 3: Evaluation methodology material

Supporting paper 3 of the second GAVI evaluation.

13 September 2010

Second GAVI evaluation: Strategic Goal 3 report

This report provides the detailed analysis and evaluation material for Strategic Goal (SG) 3 in GAVI Phase II (2006-2010). GAVI's Strategic Goal 3 is: "to increase the predictability and sustainability of long-term financing for national immunisation programs."

13 September 2010

Supporting Paper 10.1: SG1 report annexes

This annex aims to illustrate the type, nature and extent of GAVI funding to date for strategic goal 1 programmes.

13 September 2010

Supporting Paper 4.2: Mali country study report

The report provides contextual information on Mali’s health and immunisation sector, and assesses the results and value add of GAVI programs in the country.

13 September 2010

Supporting Paper 8: GAVI second evaluation, Performance evaluation assessment

The document sets out progress on indicators and outputs for each of the four strategic goals as listed in the Revised GAVI Alliance Strategy 2007-10 (Annex source 2).

13 September 2010

Supporting Paper 2: List of consultations

List of consultations on the second GAVI evaluation.

 

13 September 2010

Second GAVI evaluation: Strategic Goal 1 report

 

This report provides the detailed analysis and evaluation material for Strategic Goal (SG) 1 in GAVI Phase II (2006-2010). GAVI's Strategic Goal 1 is: "to contribute to strengthening the capacity of the health system to deliver immunisation and other health services in a sustainable manner."

13 September 2010

Second GAVI evaluation: Strategic Goal 2 report

This report provides the detailed analysis and evaluation material for Strategic Goal (SG) 3 in GAVI Phase II (2006-2010). The GAVI Alliance's second strategic goal is to "Accelerate the uptake and use of underused and new vaccines and associated technologies and improve vaccine supply stability."

13 September 2010

Supporting Paper 4.3: Nigeria country study report

The report provides contextual information on Nigeria in terms of its health and immunisation sector, and assesses the results and value add of GAVI programs in the country. The key conclusions are based on evidence gathered during a field visit to Nigeria in the week of 12 April, and desk research.

13 September 2010

Supporting Paper 9: Literature review summary

Supporting paper 9 of the second GAVI evaluation.

06 September 2010

Management response to the Second GAVI Evaluation

This paper provides a response to the Second GAVI evaluation's main findings. The evaluation is a substantial, detailed and robust piece of work which has already been of great assistance to the Secretariat. The Secretariat substantially agrees with the findings of the evaluation, and indeed has been taking account of the emerging evaluation findings in developing GAVI's five year strategy, the business plan which will implement it, and in new policies.

06 September 2010

Second GAVI evaluation: Recommendations paper

This document should therefore be read alongside the full Evaluation Report which sets conclusions on the results and value add achieved by the Alliance across its Strategic Goals. The aim is to supplement the evaluation document with a more forward-looking perspective on GAVI.

01 September 2010

Serotype Replacement Note - Prepared by the IAC

The serotype replacement issue arises from extensive use of pneumococcal conjugate vaccine, which is expected to result in some increase of disease occurence due to serotypes not in the vaccine. This raises question whether the increases could reach a point where the benefit of the vaccine is lost, or the increases will be small relative to the decline in vaccine type disease.

23 August 2010

AMC IAC eligibility determination meeting: 23 August 2010

The purpose of the meeting was to review Pfizer’s application for AMC eligibility for Prevenar 13 and determine if the candidate vaccine met the TPP for the AMC.

30 June 2010

Management response to review of GAVI Independent Review Committees

GAVI Alliance management response to the findings of a review of GAVI's Independent Review Committees (IRCs).

16 June 2010

Remaining AMC offer amount 2010

The official formal notification of the remaining AMC Offer Amount.

16 April 2010

Minutes from AMC Eligibility Determination Meeting April 2010

Minutes from AMC Eligibility Determination Meeting held in London, UK on 16 April 2010.

16 April 2010

PneumoADIP

PneumoADIP is a small, dedicated team based at Johns Hopkins Bloomberg School of Public Health, supported by a $30 million grant from the GAVI Alliance.

31 March 2010

2010 Pneumococcal AMC Annual Report

This progress report presents an overview of the activities linked to the implementation of the pneumococcal AMC since the signature of the legal agreements on 12 June 2009 up until 31 March 2010. It was developed by the AMC Secretariat at GAVI, in collaboration with the World Bank and UNICEF’s Supply Division, and was approved by the Independent Assessment Committee on 13 April 2010.

30 March 2010

Review of GAVI Independent Review Committees

The report presents the findings of a review of GAVI's Independent Review Committees (IRCs). The review was commissioned by GAVI and undertaken by HLSP (a consultancy company). The review period was 2006-2009, with the primary purpose of the review being to assess the IRC ‘fit for purpose’.

 



close icon

modal window here